Conclusion
Met significantly ameliorated UC by inhibiting NLRP3 inflammasome activation in macrophages. The underlying mechanisms not only involved the inhibition of NF-κB signaling pathway activation (first signal), but was also associated with up-regulation of UCP2 and NCF1 levels and thus the repression of ROS generation (second signal).
Methods
C57BL/6J mice were administrated with DSS solution to establish UC model. Disease Activity Index (DAI) and hematoxylin and eosin staining (HE) were performed to evaluate the impact of Met on UC model. Enzyme-linked immunosorbent assay (ELISA), Reverse transcription - quantitative polymerase chain reaction (RT-qPCR), Western blotting (WB), immunohistochemistry, and immunofluorescence were used to detect NLRP3 inflammasome activation in vivo. Furthermore, in vitro, bone marrow-derived macrophages (BMDMs) selected to clarify the role of Met on NLRP3 inflammasome activation and the underlying mechanisms.
Purpose
Metformin (Met) is widely used to treat a variety of diseases, but its role in ulcerative colitis (UC) has not been fully elucidated. This study aimed to clarify the effect of Met on UC, exploring its relationship with NLRP3 inflammasome and elucidating the potential mechanisms.
Results
In vivo, Met could significantly inhibit the development of UC, characterized by decreased DAI, increased body weight and colorectal length, and the repair of damaged tissue. Met could also block macrophage infiltration and subsequently reduced the level of IL-1β, NLRP3, and Caspase-1 in the colorectal tissue, which were mainly expressed by macrophages. In addition, the level of IL-1β in serum was remarkedly down-regulated by Met. In vitro, Met could inhibit NLRP3 inflammasome activation and subsequently dampen the maturation of pro-caspase-1 and pro-IL-1β. Moreover, Met could simultaneously suppress the activation of NF-κB/p65 signaling pathway and disrupt the formation of ASC speck. At last, Met exhibited an anti-oxidant effect, along with upregulating the level of UCP2 and NCF1.